Tran Thang, Vu Thang Hong, Vo Hoan Quoc, Thi Nguyen Hoa, Van Nguyen Hung
Medical Oncology 4, National Cancer Hospital.
Hanoi Oncology Hospital.
Ann Med Surg (Lond). 2023 May 17;85(6):2390-2394. doi: 10.1097/MS9.0000000000000858. eCollection 2023 Jun.
Although primary gastrointestinal non-Hodgkin lymphoma (GI NHL) is a rare hematopoietic malignancy, it is the most common extranodal site involved by lymphoma. Treatment methods are chosen based on many factors, including site of lesion, histopathology, symptoms, and patients' choice.
To evaluate the clinical characteristics, treatment results and prognosis for primary GI NHL in Vietnamese patients.
This was a retrospective descriptive study on 126 patients with primary GI NHL treated at our hospital from 2010 to 2015. Data of all patients were collected and analyzed.
B-cell non-Hodgkin's lymphoma was the major pathology with rate of 93.7%, in which Diffuse Large B-Cell Lymphoma type accounted for 58.7%, followed by Mucosa-associated lymphoid tissue lymphoma type 22.2%. Less common forms were cystic type, Burkitt's lymphoma, Mantle cell, T cell. The majority of patients receiving chemotherapy achieved a complete response, up to 70%. Overall survival and 5-year disease-free survival were 74.1% and 59.3%, respectively. Overall, stomach lymphoma had a longer survival rate than those in the small intestine. Factors including Eastern Cooperative Oncology Group score of 2-4, elevated Lactate Dehydrogenase levels at baseline, stage of widespread illness (III/IV), high malignancy histopathology, and lesion size of more than 10 cm were poor prognostic indicators.
Gastric lesion was the most frequent site and has better prognosis than other locations. Other prognostic factors for overall survival included Eastern Cooperative Oncology Group score, Lactate Dehydrogenase levels, stage, histopathology, and lesion size.
尽管原发性胃肠道非霍奇金淋巴瘤(GI NHL)是一种罕见的造血系统恶性肿瘤,但它是淋巴瘤累及的最常见结外部位。治疗方法的选择基于多种因素,包括病变部位、组织病理学、症状和患者的选择。
评估越南原发性GI NHL患者的临床特征、治疗结果和预后。
这是一项对2010年至2015年在我院接受治疗的126例原发性GI NHL患者进行的回顾性描述性研究。收集并分析了所有患者的数据。
B细胞非霍奇金淋巴瘤是主要病理类型,发生率为93.7%,其中弥漫性大B细胞淋巴瘤类型占58.7%,其次是黏膜相关淋巴组织淋巴瘤类型22.2%。较少见的类型有囊性型、伯基特淋巴瘤、套细胞淋巴瘤、T细胞淋巴瘤。大多数接受化疗的患者达到完全缓解,高达70%。总生存率和5年无病生存率分别为74.1%和59.3%。总体而言,胃淋巴瘤的生存率高于小肠淋巴瘤。包括东部肿瘤协作组评分为2 - 4分、基线乳酸脱氢酶水平升高、广泛疾病分期(III/IV期)、高恶性组织病理学以及病变大小超过10厘米等因素是不良预后指标。
胃部病变是最常见的部位,且预后比其他部位好。总体生存的其他预后因素包括东部肿瘤协作组评分、乳酸脱氢酶水平、分期、组织病理学和病变大小。